Metastatic Gastric Cancer Outcomes Informed by Single-Cell Transcriptome Profiles
By LabMedica International staff writers Posted on 21 Jan 2021 |
Image: Photomicrograph of omental nodules indicated an adenocarcinoma infiltrating the adipose and fibrous tissues (Photo courtesy of Beijing Shijitan Hospital).
Peritoneal Carcinomatosis (PC) is a late stage manifestation of several gastrointestinal malignancies including appendiceal, colorectal, and gastric cancer. In PC, tumors metastasize to and deposit on the peritoneal surface and often leave patients with only palliative treatment options.
Single cell sequencing examines the sequence information from individual cells with optimized next-generation sequencing (NGS) technologies, providing a higher resolution of cellular differences and a better understanding of the function of an individual cell in the context of its microenvironment.
Molecular Biologists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) performed single-cell transcriptome profiling of (PC) from 15 patients with gastric adenocarcinoma (GAC), constructed a map of 45,048 PC cells, profiled the transcriptome states of tumor cell populations, incisively explored Intra-Tumoral Heterogeneity (ITH) of malignant PC cells and identified significant correlates with patient survival.
The scientists subsequently validated that prognostic signature, which appeared to divide the tumors into groups with "gastric-dominant" or "gastrointestinal-mixed" groups, using data for another 1,336 gastric adenocarcinoma cases considered for the Cancer Genome Atlas project and three other large cohorts. The investigators uncovered the diversity in tumor cell lineage/state compositions in PC specimens and defined it as a key contributor to ITH. Single-cell analysis of ITH classified PC specimens into two subtypes that were prognostically independent of clinical variables, and a 12-gene prognostic signature was derived and validated in multiple large-scale GAC cohorts.
Linghua Wang, MD, PhD, an Assistant Professor in Genomic Medicine and co-senior author of the study, said, “The intriguing aspect is that, by classifying tumor cells based on lineage compositions, we noted two groups of patients. The more gastric-like peritoneal carcinomatosis cells had an aggressive phenotype and were associated with shorter survival. However, the more intestine-like peritoneal carcinomatosis cells were less aggressive, and patients had longer survival.”
The authors concluded that the prognostic signature appears fundamental to GAC carcinogenesis and progression and could be practical for patient stratification. The study was published on January 4, 2021 in the journal Nature Medicine.
Related Links:
University of Texas MD Anderson Cancer Center
Single cell sequencing examines the sequence information from individual cells with optimized next-generation sequencing (NGS) technologies, providing a higher resolution of cellular differences and a better understanding of the function of an individual cell in the context of its microenvironment.
Molecular Biologists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) performed single-cell transcriptome profiling of (PC) from 15 patients with gastric adenocarcinoma (GAC), constructed a map of 45,048 PC cells, profiled the transcriptome states of tumor cell populations, incisively explored Intra-Tumoral Heterogeneity (ITH) of malignant PC cells and identified significant correlates with patient survival.
The scientists subsequently validated that prognostic signature, which appeared to divide the tumors into groups with "gastric-dominant" or "gastrointestinal-mixed" groups, using data for another 1,336 gastric adenocarcinoma cases considered for the Cancer Genome Atlas project and three other large cohorts. The investigators uncovered the diversity in tumor cell lineage/state compositions in PC specimens and defined it as a key contributor to ITH. Single-cell analysis of ITH classified PC specimens into two subtypes that were prognostically independent of clinical variables, and a 12-gene prognostic signature was derived and validated in multiple large-scale GAC cohorts.
Linghua Wang, MD, PhD, an Assistant Professor in Genomic Medicine and co-senior author of the study, said, “The intriguing aspect is that, by classifying tumor cells based on lineage compositions, we noted two groups of patients. The more gastric-like peritoneal carcinomatosis cells had an aggressive phenotype and were associated with shorter survival. However, the more intestine-like peritoneal carcinomatosis cells were less aggressive, and patients had longer survival.”
The authors concluded that the prognostic signature appears fundamental to GAC carcinogenesis and progression and could be practical for patient stratification. The study was published on January 4, 2021 in the journal Nature Medicine.
Related Links:
University of Texas MD Anderson Cancer Center
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders